This event has now run. Thank you to our speakers, sponsors, and delegates who joined us in San Francisco for the Summit! If you are interested in the 2026 event, please get in touch below:
Improving Global Access to Life Changing Therapeutics
Uniting Access Teams on the West Coast to Navigate Complex Global Regulatory Hurdles, Manage Nuances in Data Collection & Streamline Operational Supply Challenges
Following the successful Boston and London meetings, the Operationalize Expanded Access Programs Summit West united stakeholders executing Early Access, Expanded Access and Post-Trial Access Programs to share expertise in successfully bridging the gap between innovative clinical research and patients in need.
This Summit was the only West Coast forum connecting Expanded Access teams with industry peers to share case studies in overcoming operational and regulatory challenges to streamline access to life-changing therapies!
60+ experts, from Eli Lilly, Gilead, Ultragenyx, Daiichi Sankyo and more joined for three jam-packed days in San Francisco in July, 2025. They gained exclusive insights, real-world case studies and cutting-edge strategies to supercharge their Expanded Access Programs.
Get in touch below and become part of the conversation next year:
REGISTER INTEREST
How We Differed from the Boston Meeting:
Brand New Session Themes: Enhancing Patient Advocacy Relationships, Developing Thoughtful & Transparent Exit Plans, and Cell & Gene Therapies: The Ideal Candidate for Expanded Access, or an Unfeasible Proposition?
Unique Networking Opportunities: Networking with previously untapped West Coast Colleagues and foster collaborative partnerships
Exciting New Speakers: From Eli Lilly, BridgeBio, Corcept Therapeutics and GE2P2 Foundation (ex-FDA Official of 41 years)
What Was There?
60+
Expanded Access Experts
16+
Expert Speakers
7+
Hours of Networking
3
Interactive Workshops
1
Ultimate Dedicated Forum
5 Not-to-Miss Sessions From 2025:
1) Operationalizing Post-Trial Access
Benjamin Rotz
Associate Vice President - Global Medical Policy, Strategy, and Operations
Eli Lilly
2) Reimbursement & Commercialization Considerations
Annie Drellas
Senior Director & Head, Office of Medical Access, Global Oncology Medical Affairs
Daiichi Sankyo
3) Expanded Access in Cell & Gene Therapies
Cara Hunt
Senior Patient Advocacy Operations Specialist
Cytokinetics
4) Optimizing Stakeholder Engagement
Becket Feierbach
Senior Director Medical Affairs
Gilead Sciences
Our 2025 Expert Partners:
Hear it from Your Peers:
“Exchanging timely knowledge and perspectives at conferences like this one is key for organizations evaluating the cost and resource requirements for implementing expanded access programs, especially within the current global political/economic environment.”
Stephen Smith, Senior Director, Program Oncology, Corcept Therapeutics
(Speaker at the Inaugural Operationalize: Expanded Access Programs West 2025)
“Not only will attending this meeting help me with my understanding of the holistic landscape of expanded access, but it helps to hear the experiences of not only other industry stakeholders, but patients, patient advocates, and physicians.”
Annie Drellas, Senior Director & Head, Office of Medical Access, Global Oncology Medical Affairs, Daiichi Sankyo
(Speaker at the Inaugural Operationalize: Expanded Access Programs West 2025)
Other Events in the Series:
